×

Biotech and Pharmaceuticals Life Sciences

  • NEW YORK _ Progenics Pharmaceuticals Inc. on Wednesday reported a loss of $16.6 million in its second quarter. The New York- based company said it had a loss of 24 cents per share. This story was generated by Automated Insights using data from Zacks Investment Research.

  • BOULDER, Colo. _ Array BioPharma Inc. on Wednesday reported a loss of $29.6 million in its fiscal fourth quarter. The average estimate of eight analysts surveyed by Zacks Investment Research was for a loss of 21 cents per share. Array BioPharma shares have dropped 10 percent since the beginning of the year.

  • WEST LAFAYETTE, Ind. _ Endocyte Inc. on Tuesday reported a loss of $11.7 million in its second quarter. On a per-share basis, the West Lafayette, Indiana- based company said it had a loss of 28 cents. This story was generated by Automated Insights using data from Zacks Investment Research.

  • MOUNTAIN VIEW, Calif. _ ChemoCentryx Inc. on Tuesday reported a loss of $9.2 million in its second quarter. The Mountain View, California- based company said it had a loss of 19 cents per share. ChemoCentryx shares have climbed 37 percent since the beginning of the year.

  • HAMPTON, N.J. _ Celldex Therapeutics Inc. on Tuesday reported a loss of $28.6 million in its second quarter. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 25 cents per share. Three analysts surveyed by Zacks expected $816,000.

  • SAN FRANCISCO _ Nektar Therapeutics on Tuesday reported a loss of $59.9 million in its second quarter. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of 35 cents per share. Five analysts surveyed by Zacks expected $36.5 million.

  • SAN DIEGO _ Halozyme Therapeutics Inc. on Tuesday reported a loss of $30.8 million in its second quarter. Halozyme Therapeutics expects full-year revenue in the range of $115 million to $130 million. Halozyme Therapeutics shares have increased 32 percent since the beginning of the year.

  • BOTHELL, Wash. _ Alder BioPharmaceuticals Inc. on Tuesday reported a loss of $74.6 million in its second quarter. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of $1.67 per share. Alder BioPharmaceuticals shares have fallen 56 percent since the beginning of the year.

  • WALTHAM, Mass. _ Tesaro Inc. on Tuesday reported a loss of $152.1 million in its second quarter. The average estimate of 12 analysts surveyed by Zacks Investment Research was for a loss of $2.52 per share. Tesaro shares have fallen nearly 8 percent since the beginning of the year.

  • SOUTH PLAINFIELD, N.J. _ PTC Therapeutics Inc. on Tuesday reported a loss of $17.5 million in its second quarter. PTC Therapeutics expects full-year revenue in the range of $155 million to $180 million. PTC Therapeutics shares have increased 75 percent since the beginning of the year.

  • NEW YORK _ Stemline Therapeutics Inc. on Tuesday reported a loss of $15.5 million in its second quarter. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 48 cents per share. Stemline Therapeutics shares have declined 17 percent since the beginning of the year.

  • GERMANTOWN, Md. _ Neuralstem Inc. on Tuesday reported a loss of $4.6 million in its second quarter. The Germantown, Maryland- based company said it had a loss of 39 cents per share. This story was generated by Automated Insights using data from Zacks Investment Research.

  • CAMBRIDGE, Mass. _ Agios Pharmaceuticals Inc. on Tuesday reported a loss of $83.1 million in its second quarter. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of $1.52 per share. Agios Pharmaceuticals shares have climbed 46 percent since the beginning of the year.

  • LEXINGTON, Mass. _ Concert Pharmaceuticals Inc. on Tuesday reported a loss of $13 million in its second quarter. On a per-share basis, the Lexington, Massachusetts- based company said it had a loss of 58 cents. Keywords: Concert Pharmaceuticals, Earnings Report.

  • LONDON, Aug 8- Gene therapy, which aims to patch faulty genes with working DNA, has been a long time in development. 2012- Europe approves Glybera, the first gene therapy in a Western market, for an ultra-rare blood disorder. 2016- Europe approves Strimvelis for a very rare type of immunodeficiency.

  • First two products struggle to win customers in Europe. LONDON, Aug 8- The science of gene therapy is finally delivering on its potential, and drugmakers are now hoping to produce commercially viable medicines after tiny sales for the first two such treatments in Europe. Yet the lack of sales for the two drugs already launched to treat ultra-rare diseases in...

  • VALENCIA, Calif. _ MannKind Corp. on Monday reported a loss of $35.3 million in its second quarter. On a per-share basis, the Valencia, California- based company said it had a loss of 35 cents. This story was generated by Automated Insights using data from Zacks Investment Research.

  • SOUTH SAN FRANCISCO, Calif. _ CytomX Therapeutics Inc. on Monday reported a loss of $25.2 million in its second quarter. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 39 cents per share. CytomX Therapeutics shares have climbed 24 percent since the beginning of the year.

  • Australia: Flesh-eating sea fleas attack teen's leg while swimming

    Mysterious sea creatures that began eating a teenager's legs in Australia were identified as "sea fleas" on Monday.

  • DUBLIN _ Strongbridge Biopharma on Monday reported a loss of $30.2 million in its second quarter. The average estimate of three analysts surveyed by Zacks Investment Research was also for a loss of 34 cents per share. Strongbridge Biopharma shares have nearly tripled since the beginning of the year.